DCs obtained from human non-small cell lung cancer (NSCLC) patients were classified into three groups based on their level of CD11c expression: CD11chigh mDC, CD11c- pDC, and a third intermediate group expressing moderate levels of CD11c. This evidence concerns the gene ITGAX and non-small cell lung carcinoma.